Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 12100 W 6th Ave LAKEWOOD 80228-1252 |
Tel: | N/A |
Website: | https://mesalabs.com |
IR: | See website |
Key People | ||
Gary M. Owens President, Chief Executive Officer, Director | John V. Sakys Chief Financial Officer, Vice President | Brian Archbold Senior Vice President - Continuous Improvement |
Business Overview |
Mesa Laboratories, Inc. is a multinational manufacturer, developer, and seller of life sciences tools and critical quality control solutions. Its segments include Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. Its Clinical Genomics segment develops, manufactures, and sells throughput genetic analysis tools used by labs to perform clinical genomic testing in several therapeutic areas. Its Sterilization and Disinfection Control segment manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization and disinfection processes. Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Calibration Solutions segment develops, manufactures, and sells quality control products used to measure or calibrate temperature, pressure, pH, humidity, and other such parameters. |
Financial Overview |
For the nine months ended 31 December 2023, Mesa Laboratories Inc revenues decreased 4% to $157.3M. Net income increased 6% to $337K. Revenues reflect Clinical Genomics segment decrease of 15% to $41.5M, Biopharmaceutical Development segment decrease of 18% to $28.5M, United States segment decrease of 11% to $79.2M, China segment decrease of less than 1% to $18.6M. |
Employees: | 698 as of Mar 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $830.67M as of Dec 31, 2023 |
Annual revenue (TTM): | $212.87M as of Dec 31, 2023 |
EBITDA (TTM): | $35.69M as of Dec 31, 2023 |
Net annual income (TTM): | $0.95M as of Dec 31, 2023 |
Free cash flow (TTM): | $37.27M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $204.74M as of Dec 31, 2023 |
Shares outstanding: | 5,394,051 as of Jan 29, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |